{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=G-PBSC+Infusion&page=2", "query": { "intervention": "G-PBSC Infusion", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=G-PBSC+Infusion&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-26T02:20:55.699Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00795132", "title": "Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Leukaemia", "Chronic Disease", "Leukemia", "Myelodysplasia", "Lymphoma" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Anti-Thymocyte Globulin", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 47, "start_date": "2004-04", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2013-07-30", "last_synced_at": "2026-09-26T02:20:55.699Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00795132" }, { "nct_id": "NCT00629798", "title": "Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Advanced Myelodysplastic Syndromes" ], "interventions": [ { "name": "Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": 64, "start_date": "2008-02-12", "completion_date": "2020-10-20", "has_results": true, "last_update_posted_date": "2021-09-24", "last_synced_at": "2026-09-26T02:20:55.699Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00629798" }, { "nct_id": "NCT00020943", "title": "Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "carmustine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 79, "start_date": "2001-06", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2016-07-19", "last_synced_at": "2026-09-26T02:20:55.699Z", "location_count": 80, "location_summary": "Anniston, Alabama • Birmingham, Alabama • La Jolla, California + 59 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020943" }, { "nct_id": "NCT02098109", "title": "Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "XM02 Filgrastim", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Apheresis", "type": "PROCEDURE" }, { "name": "Plerixafor", "type": "DRUG" }, { "name": "Stem Cell Transplant", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2014-08-20", "completion_date": "2016-09-18", "has_results": true, "last_update_posted_date": "2017-07-18", "last_synced_at": "2026-09-26T02:20:55.699Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02098109" }, { "nct_id": "NCT02128230", "title": "UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "myPRS", "type": "DEVICE" }, { "name": "Induction 1 - MEL-10+CFZ-TD-PACE", "type": "DRUG" }, { "name": "First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic)", "type": "DRUG" }, { "name": "Inter-Therapy - MEL-20+CFZ-TD-PACE (75%)", "type": "DRUG" }, { "name": "Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic)", "type": "DRUG" }, { "name": "Consolidation - CFZ-TD-PACE", "type": "DRUG" }, { "name": "Maintenance - CFZ-R(T)-D", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 20, "start_date": "2014-06-10", "completion_date": "2019-02-19", "has_results": true, "last_update_posted_date": "2021-06-22", "last_synced_at": "2026-09-26T02:20:55.699Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02128230" }, { "nct_id": "NCT03240861", "title": "Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HLA-A*0201 Positive Cells Present", "Locally Advanced Malignant Neoplasm", "NY-ESO-1 Positive", "Unresectable Malignant Neoplasm", "Sarcoma" ], "interventions": [ { "name": "18F-FHBG", "type": "OTHER" }, { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Cellular Therapy", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Plerixafor", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 5, "start_date": "2017-07-26", "completion_date": "2023-10-19", "has_results": false, "last_update_posted_date": "2023-11-01", "last_synced_at": "2026-09-26T02:20:55.699Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03240861" }, { "nct_id": "NCT00006261", "title": "Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "FEMALE", "summary": "18 Years to 60 Years · Female only" }, "enrollment_count": 0, "start_date": "2000-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-06-10", "last_synced_at": "2026-09-26T02:20:55.699Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006261" }, { "nct_id": "NCT00176865", "title": "Stem Cell Transplant for Immunologic or Histiocytic Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hemophagocytic Lymphohistiocytosis", "X-Linked Lymphoproliferative Disorders", "Chediak-Higashi Syndrome", "Griscelli Syndrome", "Immunologic Deficiency Syndromes", "Langerhans-Cell Histiocytosis" ], "interventions": [ { "name": "Stem Cell Transplant", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Anti-thymocyte globulin (ATG)", "type": "DRUG" }, { "name": "Campath 1H", "type": "DRUG" }, { "name": "Cyclosporin A", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Intravenous immunoglobulin (IVIG)", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "35 Years", "sex": "ALL", "summary": "Up to 35 Years" }, "enrollment_count": 19, "start_date": "2002-08", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2017-12-28", "last_synced_at": "2026-09-26T02:20:55.699Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00176865" }, { "nct_id": "NCT00083551", "title": "UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Thalidomide", "type": "DRUG" }, { "name": "Ara-C", "type": "DRUG" }, { "name": "BCNU", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cytoxan", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Recombinant GM-CSF", "type": "DRUG" }, { "name": "Interferon-alpha-2b", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 668, "start_date": "1998-08", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2015-11-23", "last_synced_at": "2026-09-26T02:20:55.699Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00083551" }, { "nct_id": "NCT03600909", "title": "A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fanconi Anemia", "Myelodysplastic Syndrome (MDS)", "Acute Myelogenous Leukemia (AML)" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Anti-Thymocyte Globulin (Rabbit)", "type": "DRUG" }, { "name": "The CliniMACS device", "type": "DEVICE" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": null, "sex": "ALL", "summary": "1 Month and older" }, "enrollment_count": 3, "start_date": "2018-05-15", "completion_date": "2021-04-09", "has_results": true, "last_update_posted_date": "2022-04-12", "last_synced_at": "2026-09-26T02:20:55.699Z", "location_count": 3, "location_summary": "New York, New York • Cincinnati, Ohio • Seattle, Washington", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03600909" } ] }